New prospects for targeting telomerase beyond the telomere

Nature Reviews Cancer

Volumn 16, Issue 8, 2016, Pages 508-524

  Arndt, Greg M ^a   MacKenzie, Karen L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DYSKERIN; RIBONUCLEOPROTEIN; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; ENZYME INHIBITOR; RNA;

BIOGENESIS; DRUG TARGETING; ENZYME STRUCTURE; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TELOMERE; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; ENZYMOLOGY; GENETICS; HIGH THROUGHPUT SCREENING; METABOLISM; NEOPLASMS; PATHOLOGY; SYNTHESIS;

DRUG DESIGN; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEOPLASMS; RNA; TELOMERASE; TELOMERE;

EID: 84976277532     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.55     Document Type: Review

References (223)

1. Shay, J. W., & Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33, 787-791 (1997
2. Kim, N. W., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994
3. Greider, C. W., & Blackburn, E. H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43, 405-413 (1985
4. Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W., & Harley, C. B. Telomere end-replication problem and cell aging. J. Mol. Biol. 225, 951-960 (1992
5. Harley, C. B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 8, 167-179 (2008
6. Akiyama, M., et al. Effects of oligonucleotide N3′→P5′ thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 63, 6187-6194 (2003
7. Asai, A., et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63, 3931-3939 (2003
8. Wang, E. S., et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 103, 258-266 (2004
9. Baerlocher, G. M., et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N. Engl. J. Med. 373, 920-928 (2015
10. Tefferi, A., et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N. Engl. J. Med. 373, 908-919 (2015
11. Chiappori, A. A., et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. Ann. Oncol. 26, 354-362 (2015
12. Harley, C. B., Futcher, A. B., & Greider, C. W. Telomeres shorten during ageing of human fibroblasts. Nature 345, 458-460 (1990
13. D'Adda di Fagagna, F., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003
14. Bodnar, A. G., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279, 349-352 (1998
15. Hanahan, D., & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011
16. Feng, J., et al. The RNA component of human telomerase. Science 269, 1236-1241 (1995
17. Meyerson, M., et al. hEST2, the putative human telomerase catalytic subunit gene, is up regulated in tumor cells and during immortalization. Cell 90, 785-795 (1997
18. Weinrich, S. L., et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet. 17, 498-502 (1997
19. Kilian, A., et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6, 2011-2019 (1997
20. Harrington, L., et al. Human telomerase contains evolutionarily conserved catalytic and structural subunits. Genes Dev. 11, 3109-3115 (1997
21. Nakamura, T. M., et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 277, 955-959 (1997
22. Cohen, S. B., et al. Protein composition of catalytically active human telomerase from immortal cells. Science 315, 1850-1853 (2007
23. Mitchell, J. R., Wood, E., & Collins, K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402, 551-555 (1999
24. Fu, D., & Collins, K. Purification of human telomerase complexes identifies factors involved in telomerase biogenesis and telomere length regulation. Mol. Cell 28, 773-785 (2007
25. Sauerwald, A., et al. Structure of active dimeric human telomerase. Nat. Struct. Mol. Biol. 20, 454-460 (2013
26. Miracco, E. J., Jiang, J., Cash, D. D., & Feigon, J. Progress in structural studies of telomerase. Curr. Opin. Struct. Biol. 24, 115-124 (2014
27. Jiang, J., et al. The architecture of Tetrahymena telomerase holoenzyme. Nature 496, 187-192 (2013
28. Maritz, M. F., Richards, L. A., & Mackenzie, K. L. Assessment and quantification of telomerase enzyme activity. Methods Mol. Biol. 965, 215-231 (2013
29. Damm, K., et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20, 6958-6968 (2001
30. Seimiya, H., et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST 312, MST 295, and MST 1991. Mol. Cancer Ther. 1, 657-665 (2002
31. Naasani, I., Seimiya, H., Yamori, T., & Tsuruo, T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59, 4004-4011 (1999
32. Hayakawa, N., et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 38, 11501-11507 (1999
33. Yaswen, P., et al. Therapeutic targeting of replicative immortality. Semin. Cancer Biol. 5 (Suppl.) S104-S128 (2015
34. Jagadeesh, S., Kyo, S., & Banerjee, P. P. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res. 66, 2107-2115 (2006
35. Ramachandran, C., Fonseca, H. B., Jhabvala, P., Escalon, E. A., & Melnick, S. J. Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF 7 breast cancer cell line. Cancer Lett. 184, 1-6 (2002
36. Wong, L. H., et al. A yeast chemical genetic screen identifies inhibitors of human telomerase. Chem. Biol. 20, 333-340 (2013
37. Strahl, C., & Blackburn, E. H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell. Biol. 16, 53-65 (1996
38. Shin ya, K., et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J. Am. Chem. Soc. 123, 1262-1263 (2001
39. Izbicka, E., et al. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des. 14, 355-365 (1999
40. Tauchi, T., et al. Telomerase inhibition with a novel G quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25, 5719-5725 (2006
41. Tauchi, T., et al. Activity of a novel G quadruplex-interactive telomerase inhibitor, telomestatin (SOT 095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 22, 5338-5347 (2003
42. Maritz, M. F., Napier, C. E., Wen, V. W., & MacKenzie, K. L. Targeting telomerase in hematologic malignancy. Future Oncol. 6, 769-789 (2010
43. Herbert, B. S., et al. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24, 5262-5268 (2005
44. US National Library of Medicine. Clinical Trials.gov https://Clinical Trials.gov/ct2/show/NCT00124189 (2015
45. US National Library of Medicine. Clinical Trials.gov https://Clinical.Trials.gov/ct2/show/NCT01273090 (2014
46. US National Library of Medicine. Clinical Trials.gov https://Clinical Trials.gov/ct2/show/NCT02598661 (2016
47. Thompson, P. A., et al. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin. Cancer Res. 19, 6578-6584 (2013
48. Engelhardt, M., Mackenzie, K., Drullinsky, P., Silver, R. T., & Moore, M. A. Telomerase activity and telomere length in acute and chronic leukemia, pre-and post ex vivo culture. Cancer Res. 60, 610-617 (2000
49. Schuller, C. E., Jankowski, K., & Mackenzie, K. L. Telomere length of cord blood-derived CD34+ progenitors predicts erythroid proliferative potential. Leukemia 21, 983-991 (2007
50. Jackson, S. R., et al. Antiadhesive effects of GRN163L -an oligonucleotide N3′→P5′ thio-phosphoramidate targeting telomerase. Cancer Res. 67, 1121-1129 (2007
51. Frazier, K. S. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol. Pathol. 43, 78-89 (2015
52. Yi, X., Shay, J. W., & Wright, W. E. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 29, 4818-4825 (2001
53. Ducrest, A. L., Szutorisz, H., Lingner, J., & Nabholz, M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 21, 541-552 (2002
54. Counter, C. M., et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 16, 1217-1222 (1998
55. Vaziri, H., & Benchimol, S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279-282 (1998
56. MacKenzie, K. L., Franco, S., May, C., Sadelain, M., & Moore, M. A. Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. Exp. Cell Res. 259, 336-350 (2000
57. MacKenzie, K. L., et al. Multiple stages of malignant transformation of human endothelial cells modelled by co expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N ras. Oncogene 21, 4200-4211 (2002
58. Kiyono, T., et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84-88 (1998
59. Xie, M., Podlevsky, J. D., Qi, X., Bley, C. J., & Chen, J. J. A novel motif in telomerase reverse transcriptase regulates telomere repeat addition rate and processivity. Nucleic Acids Res. 38, 1982-1996 (2010
60. Peng, Y., Mian, I. S., & Lue, N. F. Analysis of telomerase processivity: mechanistic similarity to HIV 1 reverse transcriptase and role in telomere maintenance. Mol. Cell 7, 1201-1211 (2001
61. Gillis, A. J., Schuller, A. P., & Skordalakes, E. Structure of the Tribolium castaneum telomerase catalytic subunit TERT. Nature 455, 633-637 (2008
62. Jacobs, S. A., Podell, E. R., & Cech, T. R. Crystal structure of the essential N terminal domain of telomerase reverse transcriptase. Nat. Struct. Mol. Biol. 13, 218-225 (2006
63. Lingner, J., et al. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 276, 561-567 (1997
64. Stewart, S. A., et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl Acad. Sci. USA 99, 12606-12611 (2002
65. Fleisig, H. B., & Wong, J. M. Telomerase promotes efficient cell cycle kinetics and confers growth advantage to telomerase-negative transformed human cells. Oncogene 31, 954-965 (2012
66. Sharma, G. G., et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 22, 131-146 (2003
67. Gonzalez, O. G., et al. Telomerase stimulates ribosomal DNA transcription under hyperproliferative conditions. Nat. Commun. 5, 4599 (2014
68. Smith, L. L., Coller, H. A., & Roberts, J. M. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol. 5, 474-479 (2003
69. Mukherjee, S., Firpo, E. J., Wang, Y., & Roberts, J. M. Separation of telomerase functions by reverse genetics. Proc. Natl Acad. Sci. USA 108, E1363-E1371 (2011
70. Ludwig, A., et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 61, 3053-3061 (2001
71. Cao, Y., Li, H., Deb, S., & Liu, J. P. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 21, 3130-3138 (2002
72. Luiten, R. M., Pene, J., Yssel, H., & Spits, H. Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T cell clones and confers resistance to oxidative stress-induced apoptosis. Blood. 101, 4512-4519 (2003
73. Dudognon, C., et al. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 23, 7469-7474 (2004
74. Saretzki, G., Ludwig, A., von Zglinicki, T., & Runnebaum, I. B. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 8, 827-834 (2001
75. Kraemer, K., et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. 9, 3794-3800 (2003
76. Gandellini, P., et al. Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem. Pharmacol. 73, 1703-1714 (2007
77. Baird, D. M., et al. Telomere instability in the male germline. Hum. Mol. Genet. 15, 45-51 (2006
78. Xu, L., & Blackburn, E. H. Human cancer cells harbor T stumps, a distinct class of extremely short telomeres. Mol. Cell 28, 315-327 (2007
79. Choi, J., et al. TERT promotes epithelial proliferation through transcriptional control of a Myc-and Wnt-related developmental program. PLoS Genet. 4, e10 (2008
80. Maida, Y., et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 461, 230-235 (2009
81. Koh, C. M., et al. Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity. J. Clin. Invest. 125, 2109-2122 (2015
82. Ghosh, A., et al. Telomerase directly regulates NF κB-dependent transcription. Nat. Cell Biol. 14, 1270-1281 (2012
83. Park, J. I., et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460, 66-72 (2009
84. Listerman, I., Gazzaniga, F. S., & Blackburn, E. H. An investigation of the effects of the core protein telomerase reverse transcriptase on Wnt signaling in breast cancer cells. Mol. Cell. Biol. 34, 280-289 (2014
85. Strong, M. A., et al. Phenotypes in mTERT+/-and mTERT-/-mice are due to short telomeres, not telomere-independent functions of telomerase reverse transcriptase. Mol. Cell. Biol. 31, 2369-2379 (2011
86. Luo, J., Solimini, N. L., & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009
87. Kondo, Y., et al. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16, 2243-2248 (1998
88. Zhang, P., Chan, S. L., Fu, W., Mendoza, M., & Mattson, M. P. TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14 3 3 protein-binding ability. FASEB J. 17, 767-769 (2003
89. Shin, K. H., et al. Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity. Clin. Cancer Res. 10, 2551-2560 (2004
90. Masutomi, K., et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl Acad. Sci. USA 102, 8222-8227 (2005
91. Lue, N. F., et al. Telomerase can act as a template-and RNA-independent terminal transferase. Proc. Natl Acad. Sci. USA 102, 9778-9783 (2005
92. Xi, L., & Cech, T. R. Inventory of telomerase components in human cells reveals multiple subpopulations of hTR and hTERT. Nucleic Acids Res. 42, 8565-8577 (2014
93. Akincilar, S. C., et al. Quantitative assessment of telomerase components in cancer cell lines. FEBS Lett. 589, 974-984 (2015
94. Kellermann, G., et al. Identification of human telomerase assembly inhibitors enabled by a novel method to produce hTERT. Nucleic Acids Res. 43, e99 (2015
95. Higueruelo, A. P., Jubb, H., & Blundell, T. L. Protein-protein interactions as druggable targets: recent technological advances. Curr. Opin. Pharmacol. 13, 791-796 (2013
96. Folini, M., et al. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur. J. Cancer 41, 624-634 (2005
97. Zaffaroni, N., Pennati, M., & Folini, M. Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs. Methods Mol. Biol. 361, 239-263 (2007
98. Takakura, M., et al. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59, 551-557 (1999
99. Greenberg, R. A., et al. Telomerase reverse transcriptase gene is a direct target of c Myc but is not functionally equivalent in cellular transformation. Oncogene 18, 1219-1226 (1999
100. Horikawa, I., Cable, P. L., Afshari, C., & Barrett, J. C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59, 826-830 (1999
101. Grasselli, A., et al. Estrogen receptor-α and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ. Res. 103, 34-42 (2008
102. Lin, S. Y., & Elledge, S. J. Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113, 881-889 (2003
103. Maida, Y., et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 21, 4071-4079 (2002
104. Cong, Y. S., Wen, J., & Bacchetti, S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8, 137-142 (1999
105. Moon, D. O., Kim, M. O., Lee, J. D., Choi, Y. H., & Kim, G. Y. Butein suppresses c Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett. 286, 172-179 (2009
106. Guo, Q. L., et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC 7721 cells. Life Sci. 78, 1238-1245 (2006
107. Bilsland, A. E., et al. Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE 4, e6459 (2009
108. Bilsland, A. E., et al. Mathematical model of a telomerase transcriptional regulatory network developed by cell-based screening: analysis of inhibitor effects and telomerase expression mechanisms. PLoS Comput. Biol. 10, e1003448 (2014
109. Horn, S., et al. TERT promoter mutations in familial and sporadic melanoma. Science 339, 959-961 (2013
110. Killela, P. J., et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc. Natl Acad. Sci. USA 110, 6021-6026 (2013
111. Li, Y., et al. Non-canonical NF κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat. Cell Biol. 17, 1327-1338 (2015
112. Avilion, A. A., et al. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res. 56, 645-650 (1996
113. Bachand, F., & Autexier, C. Functional regions of human telomerase reverse transcriptase and human telomerase RNA required for telomerase activity and RNA-protein interactions. Mol. Cell. Biol. 21, 1888-1897 (2001
114. Mitchell, J. R., & Collins, K. Human telomerase activation requires two independent interactions between telomerase RNA and telomerase reverse transcriptase. Mol. Cell 6, 361-371 (2000
115. Fu, D., & Collins, K. Distinct biogenesis pathways for human telomerase RNA and H/ACA small nucleolar RNAs. Mol. Cell 11, 1361-1372 (2003
116. Mitchell, J. R., Cheng, J., & Collins, K. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3′ end. Mol. Cell. Biol. 19, 567-576 (1999
117. Rangarajan, S., & Friedman, S. H. Design, synthesis, and evaluation of phenanthridine derivatives targeting the telomerase RNA/DNA heteroduplex. Bioorg. Med. Chem. Lett. 17, 2267-2273 (2007
118. Dominick, P. K., Keppler, B. R., Legassie, J. D., Moon, I. K., & Jarstfer, M. B. Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. Bioorg. Med. Chem. Lett. 14, 3467-3471 (2004
119. Booy, E. P., et al. The RNA helicase RHAU (DHX36) unwinds a G4 quadruplex in human telomerase RNA and promotes the formation of the P1 helix template boundary. Nucleic Acids Res. 40, 4010-4024 (2012
120. Lattmann, S., Stadler, M. B., Vaughn, J. P., Akman, S. A., & Nagamine, Y. The DEAH-box RNA helicase RHAU binds an intramolecular RNA G quadruplex in TERC and associates with telomerase holoenzyme. Nucleic Acids Res. 39, 9390-9404 (2011
121. Shadrick, W. R., et al. Discovering new medicines targeting helicases: challenges and recent progress. J. Biomol. Screen. 18, 761-781 (2013
122. Nguyen, G. H., et al. A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells. Chem. Biol. 20, 55-62 (2013
123. Keppler, B. R., & Jarstfer, M. B. Inhibition of telomerase activity by preventing proper assemblage. Biochemistry 43, 334-343 (2004
124. Katunaric, M., & Zamolo, G. Modulating telomerase activity in tumor patients by targeting dyskerin binding site for hTR. Med. Hypotheses 79, 319-320. (2012
125. Keppler, B. R., & Jarstfer, M. B. A high-throughput assay for a human telomerase protein-human telomerase RNA interaction. Anal. Biochem. 353, 75-82 (2006
126. Mills, N. L., Shelat, A. A., & Guy, R. K. Assay optimization and screening of RNA-protein interactions by AlphaScreen. J. Biomol. Screen. 12, 946-955 (2007
127. Li, S., Crothers, J., Haqq, C. M., & Blackburn, E. H. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J. Biol. Chem. 280, 23709-23717 (2005
128. Kedde, M., et al. Telomerase-independent regulation of ATR by human telomerase RNA. J. Biol. Chem. 281, 40503-40514 (2006
129. Kang, S., Im, K., Baek, J., Yoon, S., & Min, H. Macro and small over micro: macromolecules and small molecules that regulate microRNAs. Chembiochem 15, 1071-1078 (2014
130. Penchovsky, R., & Stoilova, C. C. Riboswitch-based antibacterial drug discovery using high-throughput screening methods. Expert Opin. Drug Discov. 8, 65-82 (2013
131. Ecker, D. J., & Griffey, R. H. RNA as a small-molecule drug target: doubling the value of genomics. Drug Discov. Today 4, 420-429 (1999
132. Wilson, W. D., & Li, K. Targeting RNA with small molecules. Curr. Med. Chem. 7, 73-98 (2000
133. Xavier, K. A., Eder, P. S., & Giordano, T. RNA as a drug target: methods for biophysical characterization and screening. Trends Biotechnol. 18, 349-356 (2000
134. Tran, T., & Disney, M. D. Identifying the preferred RNA motifs and chemotypes that interact by probing millions of combinations. Nat. Commun. 3, 1125 (2012
135. Baugh, C., Wang, S., Li, B., Appleman, J. R., & Thompson, P. A. SCAN -a high-throughput assay for detecting small molecule binding to RNA targets. J. Biomol. Screen. 14, 219-229 (2009
136. Pinto, I. G., Guilbert, C., Ulyanov, N. B., Stearns, J., & James, T. L. Discovery of ligands for a novel target, the human telomerase RNA, based on flexible-target virtual screening and NMR. J. Med. Chem. 51, 7205-7215 (2008
137. Irwin, J. J., & Shoichet, B. K. ZINC -a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177-182 (2005
138. Venteicher, A. S., Meng, Z., Mason, P. J., Veenstra, T. D., & Artandi, S. E. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 132, 945-957 (2008
139. Heiss, N. S., et al. X linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19, 32-38 (1998
140. Meier, U. T., & Blobel, G. NAP57, a mammalian nucleolar protein with a putative homolog in yeast and bacteria. J. Cell Biol. 127, 1505-1514 (1994
141. Hamma, T., & Ferre D'Amare, A. R. Pseudouridine synthases. Chem. Biol. 13, 1125-1135 (2006
142. Kim, N. K., Theimer, C. A., Mitchell, J. R., Collins, K., & Feigon, J. Effect of pseudouridylation on the structure and activity of the catalytically essential P6.1 hairpin in human telomerase RNA. Nucleic Acids Res. 38, 6746-6756 (2010
143. Mochizuki, Y., He, J., Kulkarni, S., Bessler, M., & Mason, P. J. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc. Natl Acad. Sci. USA 101, 10756-10761 (2004
144. Watkins, N. J., et al. Cbf5p, a potential pseudouridine synthase, and Nhp2p, a putative RNA-binding protein, are present together with Gar1p in all H BOX/ACA-motif snoRNPs and constitute a common bipartite structure. RNA 4, 1549-1568 (1998
145. Jack, K., et al. rRNA pseudouridylation defects affect ribosomal ligand binding and translational fidelity from yeast to human cells. Mol. Cell 44, 660-666 (2011
146. Montanaro, L., et al. Novel dyskerin-mediated mechanism of p53 inactivation through defective mRNA translation. Cancer Res. 70, 4767-4777 (2010
147. Montanaro, L. Dyskerin and cancer: more than telomerase. The defect in mRNA translation helps in explaining how a proliferative defect leads to cancer. J. Pathol. 222, 345-349 (2010
148. Alawi, F., & Lin, P. Dyskerin is required for tumor cell growth through mechanisms that are independent of its role in telomerase and only partially related to its function in precursor rRNA processing. Mol. Carcinog. 50, 334-345 (2011
149. Ruggero, D., et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 299, 259-262 (2003
150. Ge, J., et al. Dyskerin ablation in mouse liver inhibits rRNA processing and cell division. Mol. Cell. Biol. 30, 413-422 (2010
151. Pereboom, T. C., van Weele, L. J., Bondt, A., & MacInnes, A. W. A zebrafish model of dyskeratosis congenita reveals hematopoietic stem cell formation failure resulting from ribosomal protein-mediated p53 stabilization. Blood 118, 5458-5465 (2011
152. Boon, K., et al. N myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 20, 1383-1393 (2001
153. Iritani, B. M., & Eisenman, R. N. c Myc enhances protein synthesis and cell size during B lymphocyte development. Proc. Natl Acad. Sci. USA 96, 13180-13185 (1999
154. O'Brien, R., et al. MYC-driven neuroblastomas are addicted to a telomerase-independent function of dyskerin. Cancer Res. 76, 2206-2218 (2016
155. Rocchi, L., Barbosa, A. J., Onofrillo, C., Del Rio, A., & Montanaro, L. Inhibition of human dyskerin as a new approach to target ribosome biogenesis. PLoS ONE 9, e101971 (2014
156. Heiss, N. S., et al. Gene structure and expression of the mouse dyskeratosis congenita gene, Dkc1. Genomics 67, 153-163 (2000
157. He, J., et al. Targeted disruption of Dkc1, the gene mutated in X linked dyskeratosis congenita, causes embryonic lethality in mice. Oncogene 21, 7740-7744 (2002
158. Westin, E. R., et al. Telomere restoration and extension of proliferative lifespan in dyskeratosis congenita fibroblasts. Aging Cell 6, 383-394 (2007
159. Knight, S., et al. Dyskeratosis Congenita (DC) Registry: identification of new features of DC. Br. J. Haematol. 103, 990-996 (1998
160. Von Stedingk, K., et al. snoRNPs regulate telomerase activity in neuroblastoma and are associated with poor prognosis. Transl Oncol. 6, 447-457 (2013
161. Alawi, F., & Lin, P. Loss of dyskerin reduces the accumulation of a subset of H/ACA snoRNA-derived miRNA. Cell Cycle 9, 2467-2469 (2010
162. Montanaro, L., et al. Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer. J. Pathol. 210, 10-18 (2006
163. Sieron, P., et al. DKC1 overexpression associated with prostate cancer progression. Br. J. Cancer 101, 1410-1416 (2009
164. Kiss, T., Fayet-Lebaron, E., & Jady, B. E. Box H/ACA small ribonucleoproteins. Mol. Cell 37, 597-606 (2010
165. Dez, C., Noaillac-Depeyre, J., Caizergues-Ferrer, M., & Henry, Y. Naf1p, an essential nucleoplasmic factor specifically required for accumulation of box H/ACA small nucleolar RNPs. Mol. Cell. Biol. 22, 7053-7065 (2002
166. Darzacq, X., et al. Stepwise RNP assembly at the site of H/ACA RNA transcription in human cells. J. Cell Biol. 173, 207-218 (2006
167. Fatica, A., Dlakic, M., & Tollervey, D. Naf1 p is a box H/ACA snoRNP assembly factor. RNA 8, 1502-1514 (2002
168. Grozdanov, P. N., Roy, S., Kittur, N., & Meier, U. T. SHQ1 is required prior to NAF1 for assembly of H/ACA small nucleolar and telomerase RNPs. RNA 15, 1188-1197 (2009
169. Holt, S. E., et al. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. 13, 817-826 (1999
170. Ivanov, A. A., Khuri, F. R., & Fu, H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol. Sci. 34, 393-400 (2013
171. Osterwald, S., et al. A three-dimensional colocalization RNA interference screening platform to elucidate the alternative lengthening of telomeres pathway. Biotechnol. J. 7, 103-116 (2012
172. Stern, J. L., Zyner, K. G., Pickett, H. A., Cohen, S. B., & Bryan, T. M. Telomerase recruitment requires both TCAB1 and Cajal bodies independently. Mol. Cell. Biol. 32, 2384-2395 (2012
173. Cristofari, G., et al. Human telomerase RNA accumulation in Cajal bodies facilitates telomerase recruitment to telomeres and telomere elongation. Mol. Cell 27, 882-889 (2007
174. Venteicher, A. S., et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 323, 644-648 (2009
175. Tang, M., et al. Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance. J. Cell Sci. 128, 331-341 (2015
176. Soohoo, C. Y., et al. Telomerase inhibitor PinX1 provides a link between TRF1 and telomerase to prevent telomere elongation. J. Biol. Chem. 286, 3894-3906 (2011
177. Zhou, X. Z., & Lu, K. P. The Pin2/TRF1 interacting protein PinX1 is a potent telomerase inhibitor. Cell 107, 347-359 (2001
178. Yoo, J. E., Park, Y. N., & Oh, B. K. PinX1, a telomere repeat-binding factor 1 (TRF1)-interacting protein, maintains telomere integrity by modulating TRF1 homeostasis, the process in which human telomerase reverse transcriptase (hTERT) plays dual roles. J. Biol. Chem. 289, 6886-6898 (2014
179. Banik, S. S., & Counter, C. M. Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. J. Biol. Chem. 279, 51745-51748 (2004
180. Zhong, F. L., et al. TPP1 OB fold domain controls telomere maintenance by recruiting telomerase to chromosome ends. Cell 150, 481-494 (2012
181. Abreu, E., et al. TIN2 tethered TPP1 recruits human telomerase to telomeres in vivo. Mol. Cell. Biol. 30, 2971-2982 (2010
182. Chen, L. Y., Redon, S., & Lingner, J. The human CST complex is a terminator of telomerase activity. Nature 488, 540-544 (2012
183. Brenke, R., et al. Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques. Bioinformatics 25, 621-627 (2009
184. Bilsland, A. E., Cairney, C. J., & Keith, W. N. Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. J. Cell. Mol. Med. 15, 179-186 (2011
185. Sfeir, A., & de Lange, T. Removal of shelterin reveals the telomere end-protection problem. Science 336, 593-597 (2012
186. Bywater, M. J., et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22, 51-65 (2012
187. Quin, J. E., et al. Targeting the nucleolus for cancer intervention. Biochim. Biophys. Acta 1842, 802-816 (2014
188. Engelhardt, M., et al. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 90, 182-193 (1997
189. Wright, W. E., Piatyszek, M. A., Rainey, W. E., Byrd, W., & Shay, J. W. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18, 173-179 (1996
190. Samper, E., et al. Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells. Blood 99, 2767-2775 (2002
191. Imamura, S., et al. A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS ONE 3, e3364 (2008
192. Sarin, K. Y., et al. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436, 1048-1052 (2005
193. Drygin, D., O'Brien, S. E., Hannan, R. D., McArthur, G. A., & Von Hoff, D. D. Targeting the nucleolus for cancer-specific activation of p53. Drug Discov. Today 19, 259-265 (2014
194. Henras, A., et al. Nhp2p and Nop10p are essential for the function of H/ACA snoRNPs. EMBO J. 17, 7078-7090 (1998
195. Pogacic, V. D., F., & Filipowicz, W. Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10. Mol. Cell. Biol. 20, 9028-9040 (2000
196. Girard, J. P., et al. GAR1 is an essential small nucleolar RNP protein required for pre-rRNA processing in yeast. EMBO J. 11, 673-682 (1992
197. Liu, D., et al. PTOP interacts with POT1 and regulates its localization to telomeres. Nat. Cell Biol. 6, 673-680 (2004
198. Xin, H., et al. TPP1 is a homologue of ciliate TEBP-β and interacts with POT1 to recruit telomerase. Nature 445, 559-562 (2007
199. Nandakumar, J., et al. The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity. Nature 492, 285-289 (2012
200. Tang, J., et al. Critical role for Daxx in regulating Mdm2. Nat. Cell Biol. 8, 855-862 (2006
201. Hollenbach, A. D., McPherson, C. J., Mientjes, E. J., Iyengar, R., & Grosveld, G. Daxx and histone deacetylase II associate with chromatin through an interaction with core histones and the chromatin-associated protein Dek. J. Cell Sci. 115, 3319-3330 (2002
202. Forsythe, H. L., Jarvis, J. L., Turner, J. W., Elmore, L. W., & Holt, S. E. Stable association of hsp90 and p23, but Not hsp70, with active human telomerase. J. Biol. Chem. 276, 15571-15574 (2001
203. Isaac, C., Yang, Y., & Meier, U. T. Nopp140 functions as a molecular link between the nucleolus and the coiled bodies. J. Cell Biol. 142, 319-329 (1998
204. Yang, Y., et al. Conserved composition of mammalian box H/ACA and box C/D small nucleolar ribonucleoprotein particles and their interaction with the common factor Nopp140. Mol. Biol. Cell 11, 567-577 (2000
205. Renvoise, B., et al. The loss of the snoRNP chaperone Nopp140 from Cajal bodies of patient fibroblasts correlates with the severity of spinal muscular atrophy. Hum. Mol. Genet. 18, 1181-1189 (2009
206. Gallant, P. Control of transcription by Pontin and Reptin. Trends Cell Biol. 17, 187-192 (2007
207. Zhu, Q., et al. GNL3L stabilizes the TRF1 complex and promotes mitotic transition. J. Cell Biol. 185, 827-839 (2009
208. Du, X., et al. The homologous putative GTPases Grn1p from fission yeast and the human GNL3L are required for growth and play a role in processing of nucleolar pre-rRNA. Mol. Biol. Cell 17, 460-474 (2006
209. Sexton, A. N., & Collins, K. The 5′ guanosine tracts of human telomerase RNA are recognized by the G quadruplex binding domain of the RNA helicase DHX36 and function to increase RNA accumulation. Mol. Cell. Biol. 31, 736-743 (2011
210. Snow, B. E., et al. Functional conservation of the telomerase protein Est1p in humans. Curr. Biol. 13, 698-704 (2003
211. Reichenbach, P., et al. A human homolog of yeast Est1 associates with telomerase and uncaps chromosome ends when overexpressed. Curr. Biol. 13, 568-574 (2003
212. Page, M. F., Carr, B., Anders, K. R., Grimson, A., & Anderson, P. SMG 2 is a phosphorylated protein required for mRNA surveillance in Caenorhabditis elegans and related to Upf1p of yeast. Mol. Cell. Biol. 19, 5943-5951 (1999
213. Chawla, R., et al. Human UPF1 interacts with TPP1 and telomerase and sustains telomere leading strand replication. EMBO J. 30, 4047-4058 (2011
214. Fu, W., Lu, C., & Mattson, M. P. Telomerase mediates the cell survival-promoting actions of brain derived neurotrophic factor and secreted amyloid precursor protein in developing hippocampal neurons. J. Neurosci. 22, 10710-10719 (2002
215. Zhu, J., Wang, H., Bishop, J. M., & Blackburn, E. H. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc. Natl Acad. Sci. USA 96, 3723-3728 (1999
216. Li, S., Ferguson, M. J., Hawkins, C. J., Smith, C., & Elwood, N. J. Human telomerase reverse transcriptase protects hematopoietic progenitor TF 1 cells from death and quiescence induced by cytokine withdrawal. Leukemia 20, 1270-1278 (2006
217. Nitta, E., et al. Telomerase reverse transcriptase protects ATM-deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere-independent mechanism. Blood 117, 4169-4180 (2011
218. Gomez, D. E., Armando, R. G., & Alonso, D. F. AZT as a telomerase inhibitor. Front. Oncol. 2, 113 (2012
219. Hukezalie, K. R., Thumati, N. R., Cote, H. C., & Wong, J. M. In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. PLoS ONE 7, e47505 (2012
220. El Daly, H., et al. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105, 1742-1749 (2005
221. Naasani, I., Seimiya, H., & Tsuruo, T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. 249, 391-396 (1998
222. Gowan, S. M., Heald, R., Stevens, M. F., & Kelland, L. R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G quadruplexes. Mol. Pharmacol. 60, 981-988 (2001
223. Villa, R., et al. Inhibition of telomerase activity by geldanamycin and 17 allylamino, 17 demethoxygeldanamycin in human melanoma cells. Carcinogenesis 24, 851-859 (2003